Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 [Yahoo! Finance]
Equillium, Inc. (EQ)
Last equillium, inc. earnings: 3/26 04:07 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
EQ504 has a unique, multi-modal, non-immunosuppressive mechanism of action that is complementary to other immuno-inflammatory therapeutics EQ504 data to be presented in three poster presentations next week at the annual meeting of the American Association of Immunologists (AAI) LA JOLLA, Calif., May 01, 2025 BUSINESS WIRE )--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced the advancement of a novel and potent aryl hydrocarbon receptor (AhR) modulator (EQ504), which was acquired through the acquisition of Ariagen, a biotechnology company that was majority owned by Equillium's largest investor, Decheng Capital. AhR is critical to barrier organ tissue physiology and immunology, where it maintains barrier function, promotes tissue repair and regeneration, and regulates resident immune cells and anti-inflammatory res
Show less
Read more
Impact Snapshot
Event Time:
EQ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EQ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EQ alerts
High impacting Equillium, Inc. news events
Weekly update
A roundup of the hottest topics
EQ
News
- Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists [Yahoo! Finance]Yahoo! Finance
- Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of ImmunologistsBusiness Wire
- Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504Business Wire
- Equillium Announces Feedback from the U.S. Food and Drug AdministrationBusiness Wire
- Equillium, Inc. (NASDAQ: EQ) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.MarketBeat
EQ
Earnings
- 3/27/25 - Beat
EQ
Sec Filings
- 6/13/25 - Form 8-K
- 6/12/25 - Form 144
- 5/23/25 - Form 4
- EQ's page on the SEC website